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Syk inhibitorsReactive Oxygen Species (ROS) are crucial tomultiple biological processes involved in the pathophysiology of in-
flammation, and are also involved in redox signaling responses. Although previous reports have described an as-
sociation between oxidative events and the modulation of innate immunity, a role for redox signaling in T cell
mediated adaptive immunity has not been described yet. This work aims at assessing if T cells can sense redox
stress through protein sulfhydryl oxidation and respond with tyrosine phosphorylation changes. Our data
show that Jurkat T cells respond to –SH group oxidation with specific tyrosine phosphorylation events. The re-
lease of T cell cytokines TNF, IFNγ and IL2 as well as the expression of a number of receptors are affected by
those changes. Additionally, experiments with spleen tyrosine kinase (Syk) inhibitors showed a major involve-
ment of Syk in these responses. The experiments described herein show a link between cysteine oxidation and
tyrosine phosphorylation changes in T cells, as well as a novel mechanism by which Syk inhibitors exert their
anti-inflammatory activity through the inhibition of a response initiated by ROS.
© 2014 Elsevier Inc. All rights reserved.1 . Introduction
Reactive Oxygen Species (ROS) can be considered not only as a
source of oxidative stress but also as triggers or second messengers in
intracellular signaling. They can potentially induce andmodulate a vari-
ety of biological responses including gene expression, cytokine produc-
tion, differentiation, proliferation and apoptosis [1–4].
Several studies have revealed that ROSmay act upon downstream tar-
gets within signaling cascades to regulate the activity of enzymes (e.g.
phosphatases and kinases) and transcriptional regulators through selec-
tive oxidation of the –SHmoiety of protein cysteine residues [5,6]. The se-
lective formation of a disulfide bridge through the oxidation of adjacent
protein thiols is one of the most likely mechanism of redox sensing due
to its reversibility [7,8]. To function as redox sensor a protein is expected
to contain –SH groupswith a very high reactivity, due to the high concen-
trations of the intracellular ROS scavenging molecules (GSH, thioredoxin,
etc.) [2,8]. Several proteins function asROSeffectors andare reversibly ox-
idized by ROS. Among the ROS effectors, there are tyrosine phosphatases
(PTPs), glycolytic enzymes (GAPDH, enolase), structural proteins (actin,9 079228615.myosin, tropomyosin), regulatory enzymes involved in protein synthesis
(elongation factors), folding (heat shock proteins), degradation (ubiqui-
tin, thiolesterases, proteasome components), and antioxidant defense
molecules (thioredoxin, peroxiredoxin) [2,9,7,10–13]. Several transcrip-
tion factors such as NF-KB [14,15], AP-1 [16,17] and c-jun [18,19] are
redox-regulated. It has been demonstrated that phosphorylation redox
responses are also critical in the activation of several signalingmolecules,
such as p53, B cell antigen receptor (BCR), JNK/ERK, p38-MAPK, FcγRI,
FcεRI, phosphoinositide 3-kinase (PI3K)/AKT, and JAK/STAT [20–25].
Additionally, studies on the redox regulation of erythrocyte mem-
brane stability showed that oxidation of specific cysteine residues, lo-
cated in the cytoplasmic domain of band 3 protein, induces its
tyrosine phosphorylation by Syk [20,26]. This leads to changes in pro-
tein–protein interactions that regulate the coupling between cytoskele-
ton and membrane integral proteins. This phenomenon has been
involved in several hemolytic disorders such as β-thalassemia [27],
G6PD deficiency [26], sickle-cell anemia [28], and malaria-infected red
blood cells (RBCs) [29].
The regulation of the immune system appears to be influenced by its
redox state [30,31]. As a matter of fact, chronic inflammation and in-
creased ROS concentrations are involved in different conditions such
as Alzheimer's disease [32], Parkinson's disease [33], Crohn's disease
[34], systemic lupus erythematosus [35], rheumatoid arthritis [36,37],
as well as cardiovascular diseases [38,39].
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ROS on T cells using various experimental models, such as co-
culture with monocytes/macrophages or treatments with H2O2
[40–43]. Co-culturing T cells with tumor-associated macrophages
as a source of ROS and non-cytotoxic concentration of H2O2 or di-
amide resulted in decreased expression of the T cell receptor CD3
zeta chain [43,44]. Moreover, a decrease in CD16 expression was
induced in T cells by macrophages isolated from metastatic lymph
nodes from patients with malignant melanoma or by LPS-stimulated
monocytes [40]. On the other hand, an important work of Baty et al.
about Jurkat T cells treated with H2O2 indicated the involvement of dif-
ferent redox-sensitive proteins in energy metabolism, protein degrada-
tion, structure maintenance and signaling [45]. In 2009 Mougiakakos
et al. showed that a subpopulation of T cells, Tregs, differ from other
subsets for their resistance to oxidative stress-induced cell death.
Suppression assays revealed that high concentration of H2O2, highly
toxic for helper T cells, did not affect the suppression activity of these
cells [46].
Several reports have also demonstrated that ROS mediate leuko-
cytes' recruitment to wounded areas [47–50]. It has been shown that
the Lyn kinase is activated bywound-generated H2O2, inducing the che-
motactic movement of leukocytes [51]. The Cys466 residue in Lyn ap-
pears to be the target for oxidants.
Additionally, different reports indicate that protein tyrosine phos-
phatases (PTPs) may also represent major ROS targets [52,53]. The
SH2 domain protein tyrosine phosphatase-2 (SHP-2) is oxidized and
inactivated in platelets by ROS leading to the auto-phosphorylation of
Syk and additional T cell Tyr kinases [54]. Syk is highly expressed in he-
matopoietic cells such as B cells, T cells, erythrocytes, mast cells, macro-
phages and neutrophils [55–57]. Depending on osmotic or oxidativeFig. 1. Time course of the phosphorylation and oxidation of Jurkat T cell total proteins. (A): An
ment. (B): Quantification of tyrosine phosphorylation levels performed with an IR fluorescence
stainedwith a fluorescentmaleimide probe of total Jurkat T cell proteins treatedwith 0.3 mMd
scanner (Odyssey, Licor, USA) and expressed as fluorescence arbitrary units. Values are plottedstress, Syk acts in different ways with pro-apoptotic or anti-apoptotic
activities. In the latter case, Syk may act in ERK or JUNK pathways
(leading to the inhibition of apoptosis) or on the BCR pathway [58].
Syk kinase has been widely studied as a therapeutic target in inflamma-
tion [59], neurodegenerative disorders [60], allergy [61] and cancer
[62–64]. Besides the studies performed in erythrocytes [26,27,65], the
role of cysteine oxidation on Syk activity and functions in T cells are
still unknown.
A better understanding of the molecular mechanisms involved in
oxidative signaling of T cells may have broad implications for the ther-
apy of different human diseases [66,67]. Due to the complexity of
models including cell co-cultures or using H2O2, which is rapidly de-
graded and that can generate ROS reacting in an unpredictable way,
we performed experiments with diamide to reversibly oxidize –SH
groups.
We used a T cell line (Jurkat T cells) to limit the experimental vari-
ability dependent on different blood donors, T cells subsets, and
methods used to purify cells. Using low, non-cytotoxic concentrations
of diamide, we monitored the phosphorylation response with a proteo-
mic approach and studied the functional involvement of the Lyn and
Syk kinases.
2 . Materials and methods
2.1. Cells cultures
Jurkat T cells clone E6.1 were maintained in RPMI 1640
GLUTAMAX (Life Technologies, Carlsbad, CA-USA), supplemented
with 10% (v/v) heat-inactivated fetal bovine serum (FBS, Life Tech-
nologies, Carlsbad, CA-USA), 20 mM HEPES (Sigma-Aldrich, St.ti-phosphotyrosine immunoblot of Jurkat T cell total proteins after 0.3 mM diamide treat-
detection scanner (Odyssey, Licor, USA) and expressed as arbitrary units. (C): SDS-PAGE
iamide. (D). Quantification of oxidation levels performedwith an IR fluorescence detection
as mean ± standard deviation of 3 separate experiments.
Table 1
Identification of proteins in Jurkat T cells treated with 0.3 mM diamide by MALDI-ToF.
Number of band Score Matched pept. Name Mass (Da) Accession number
1 112 24 Clathrin heavy chain 1 191,493 CLH1_HUMAN
2 71 11 Vinculin 123,799 VINC_HUMAN
3 69 8 Hypoxia up-regulated protein-1 111,335 HYOU1_HIUMAN
4 75 13 N-alpha-acetiltransferasi 15 101,208 NAA15_HUMAN
5 65 9 Nucleolar MIF4G domain containing protein 96,198 NOM1_HUMAN
6 57 11 Endoplasmin 92,411 HSP90B1_HUMAN
7 85 13 Protein kinase C binding protein 91,284 NELL2_HUMAN
8 57 9 Protein FAMM 83 G 90,779 FA83G_HUMAN
9 96 16 Heat shock protein HSP 90-alpha 84,607 HSP90AA1_HUMAN
10 80 14 Heat shock protein HSP 90-alpha 83,212 HSP90B_HUMAN
11 72 8 Prospero homeobox protein 83,151 PROX1_HUMAN
12 79 8 Non-canonical poly (A) RNA polymerase PAPD/ 82,309 PAPD/_HUMAN
13 68 16 Protein kinase C theta 81,811 KPCT_HUMAN
14 73 11 Stress-70 protein, mitochondrial 73,635 GRP75_HUMAN
15 79 9 78 kDa glucose-regulated protein 72,288 GRP78_HUMAN
16 56 9 Tyrosine-protein kinase SYK 72,066 KSYK_HUMAN
17 52 11 Heat shock cognate 71 kDa 70,854 HSP7C_HUMAN
18 56 9 WD repeat-containing protein 1 66,152 WDR1_HUMAN
19 95 12 60 kDa heat shock protein, mitochondrial 61,016 CH60_HUMAN
20 68 8 Protein disulfide-isomerase A3 56,747 PDIA3_HUMAN
21 139 14 Tubulin beta chain 49,639 TBB5_HUMAN
22 80 8 Alpha-enolase 47,139 ENOA_HUMAN
23 75 7 Actin, cytoplasmic 1 41,710 ACTB_HUMAN
24 80 7 Fructose-bisphosphate aldolase A 39,395 ALDOA_HUMAN
25 87 9 Glyceraldehyde-3-phosphate dehydrogenase 36,030 G3P_HUMAN
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(Life Technologies, Carlsbad, CA-USA) at 37 °C in a humidified atmo-
sphere 5% CO2. The cells were subcultured every 3 days at density of
6 × 105/ml with fresh medium in a 75 cm2 tissue culture flask
(Corning, NY-USA).2.2. Syk and Lyn inhibitors
Cells were pre-incubated with 5 μM Syk inhibitors II (Calbiochem,
San Diego, CA-USA) or 10 μM Lyn Inhibitor (PP2, Calbiochem, San
Diego, CA-USA) for 1 h at 37 °C before oxidant treatments. The cells
were washed with phosphate buffer saline (PBS) prior to the oxidant
treatment.2.3. Oxidant agent
Transient oxidative stresswas induced treating Jurkat T cellswith di-
amide in RPMI 1640, reported to be a specific thiol oxidizing agent [43].
Diamide (Sigma-Aldrich, St. Louis, MO-USA) was firstly tested in dose
response experiments and 0.3mMconcentrationwas chosen for our ex-
periments. Cells were incubated at 37 °C for different times to evaluate
the phosphorylation dose response and then washed four times with
PBS (150 ×g, 10 min). Viability of the cells was examined by Trypan
blue dye exclusion test (Sigma-Aldrich, St. Louis, MO-USA) and apopto-
tic index was assessed by Annexin V assay (Life Technologies, Carlsbad,
CA-USA).Table 2
Phosphopeptides of Jurkat T cells treated with 0.3 mM diamide identified by MS/MS spectrom
Accession number Protein name homo sapiens
P06239 Tyrosine-protein kinase Lck
Q06124 Tyrosine-protein phosphatase non-receptor type 11 isofor
Q00526 Cyclin-dependent kinase 3
P06239 Lymphocyte-specific protein tyrosine kinase precursor
Q9NTI5 PDS5, regulator of cohesion maintenance, homolog B
P27695 APEX nuclease2.4. MTT reduction test
To determine reductive activity, 1,5 × 105 cells were pre-incubated
with 0.3 mM diamide in RPMI 1640 (90 μl) at different time points in
each well of a 96-well plate (Corning, NY-USA). Then, the cells were in-
cubated for 4 h with 10 μl RPMI 1640 medium containing 5 mg/ml
Thiazolyl blue tetrazolium bromide (MTT, Sigma-Aldrich, St. Louis,
MO-USA). Later, the medium was removed and the converted dye was
solubilized with 0.3 ml of a MTT solvent solution constituted by 4 mM
HCl, 0.1% Nondet P-40 (NP40) all in isopropanol (Sigma-Aldrich, St.
Louis, MO-USA). Absorbance was measured at 570 nm using a micro-
plate reader (Biorad, Hercules, CA-USA) and the reduction activity was
expressed as percentage of the corresponding control.2.5. Electrophoresis and immunoblotting
Total protein content was quantified using DC Protein Assay (Biorad,
Hercules, CA-USA) andwas solubilized in Laemmli Buffer under reducing
conditions (2% beta-mercaptoethanol) in a volume ratio of 1:1. SDS-Page
analysis was conducted by heating the samples for 5 min at 100 °C and
loading 10 μg total proteins on the 8% gel for protein staining by blue
colloidal Coomassie (Sigma-Aldrich, St. Louis, MO-USA). For western
blotting analysis, 30 μg of proteins were loaded on each lane and trans-
ferred to nitrocellulose membranes. Membranes were blocked in PBS/T
(8,5 mM Na2HPO4, 1,47 mM KH2PO4, 2,68 mM KCl, 137 mM NaCl, 0.1%
Tween20) (Sigma-Aldrich, St. Louis, MO-USA). Separated proteins were
probed with anti-Syk (Cell signaling, Danvers, MA-USA), anti-pSyketry.
Identified peptides Tyrosine number
NLDNGGFYISPR Y181
m 1/2 IQNTGDYYDLYGGEK Y62
IGEGTYGVVYK Y15
SVLEDFFTATEGQYQPQP Y505
HHKSKKGPPRQAKYAIHCIHAIFSSK Y728
HLYPNTPYAYTFWTYMMNAR Y269
Fig. 2. Trypan blue viability assay andMTT reduction test of Jurkat T cells. (A): Trypan blue
assay of Jurkat T cells at different time points (from15min to 240min) of 0.3mMdiamide
oxidation. Viability is expressed as percent of total cell number (%). P value of the viability
time points was found to be statistically significant by One-way ANOVA Test (**p b 0.01).
(B):MTT reduction test of Jurkat T cells treatedwith 0.3mMdiamide. Reduction activity is
expressed as percent of untreated cells. Values are plotted as mean ± standard deviation
of 3 separate experiments. Medians and P values which were found to be statistically sig-
nificant by the t-student test are shown (*p b 0.05, **p b 0.01, ***p b 0.001).
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phosphoserine antibodies (Santa Cruz, Santa Cruz, CA-USA), all diluted
1:2000. Secondary mouse and rabbit antibodies conjugated to infrared
fluorescent dyes excitable at 800 nm (IRDye 800CW, Licor, USA) were
used (1:25,000) to visualize the desired antigens using an 800 nm laser
scanner (Odyssey, Licor, USA). Quantitative analysis of proteins on the
membranes was performed by Odyssey software (Licor, USA).
2.6. Maleimide probe
A sulfhydryl-reactive dye (DyLight 800Maleimide, Thermoscientific,
Waltham, MA-USA) was used to study the effects of 0.3 mM diamide
treatment. A 30 μl volume of treated and untreated cell pellets was
suspended in 30 μl of PBS and incubated with 0.25 mg/ml Maleimide
800 Dye for 1 h at room temperature in complete darkness. The reaction
was stopped bywashing in PBS-BSA followed by twowashes in PBS. The
cells were then solubilized for SDS-PAGE. Images were acquired using
Odyssey scanner (Licor, USA). Quantitative analysis of the probe
bound to the –SH groups of proteins was performed by Odyssey soft-
ware (Licor, USA).
2.7. Maldi-ToF analysis
Coomassie stained bands were excided from gels and proteins were
digestedwith trypsin. Each piece of gelwas de-stained by severalwashes
in 5 mM NH4HCO3/acetonitrile (50/50 v/v) and successively dried with
pure acetonitrile. The gel slices were rehydrated for 45 min at 4 °C in
20 μl of a 5 mMNH4HCO3 digestion buffer containing 10 ng/μl of trypsin
(Sigma-Aldrich, St. Louis, MO-USA). The excess of protease solution was
removed and the volume adjusted with 5mMNH4HCO3 to cover the gel
slices. Digestion was allowed to proceed overnight at 37 °C.
Samples were loaded onto MALDI target using 1 μl of the tryptic di-
gests mixed 1:1 with a solution of alpha-Cyano-4-hydroxycinnamic
acid (10 mg/ml in 0.1% acetonitrile/trifluoroacetic acid, 40/60),
(Sigma-Aldrich, St. Louis, MO-USA). MS analysis of peptides was per-
formed by aMALDI-TOFMicroMX (Micromass, Manchester, UK) work-
ing in reflectronmodality according to the tuning procedures suggested
by the manufacturer. Peak lists were generated with Proteinlynx Data
Preparation using the following parameters: external calibration with
lock mass using mass 24,651,989 Da of ACTH fragment 18–39 (Sigma-
Aldrich, St. Louis, MO-SA) background subtract with adaptive mode,
performing deisotoping with 3% threshold.
For peptide mass fingerprinting (PMF) analysis, the MS spectra were
converted into pkl files using Mass Lynx 4.0. Peak lists containing the
most intense peaks of the spectrum were sent to MASCOT PMF search
(http://www.matrixscience.com) using the Swiss-Prot database. Search
settings allowed one missed cleavage with the trypsin enzyme selected,
for 1-DE analysis and oxidation ofmethionine as potential variablemod-
ification and a peptide tolerance of 50 ppm. Only protein identifications
with significant Mascot scores (p b 0.05) were taken in consideration.
2.7.1. Sample preparation and protein digestion protocol for Triple Q-ToF
analysis
After lysis of treated Jurkat T cells using a 20% SDS, 1 M DTT, 5 μl
benzonase (250 units/μl) and 8 M Urea (Sigma-Aldrich, St. Louis, MO-
USA), samples were placed on a Ultra Centrifugal Filter Unit with PLTK
Ultracel-30 Regenerated Cellulose Membrane (Billerica, MA-USA) in
order to remove the detergent and concentrate proteins. After different
washing steps the proteins were ready for trypsin digestion. For our ex-
periments, after incubation with SDS, samples were treated following
the protocol by FASP Protein Digestion Kit (Expedeon, San Diego, CA-
USA).
2.7.2. Immunoprecipitation
After the tryptic digestion, immunoprecipitation of the tyrosine
phosphopeptides was performed. The anti-phosphotyrosine antibodybeads (Santa Cruz, Santa Cruz, CA-USA) were activated with an immu-
noprecipitation buffer (50 mMMOPS pH 7.2,10mM Sodium Phosphate
and 50 mM Sodium Chloride). The samples were incubated with the
beads at 4 °C o/n. After this step the beads were washed and the anti-
bodies were freed with 2% TFA and incubated at 55 °C.
Before and after immunoprecipitation C18 Tips (Thermo Scientific
Pierce, Waltham, MA-USA) were employed to desalt and concentrate
samples. They enabled an efficient purification of peptides and small
proteins before mass spectrometry. Finally the pooled samples were
dried in cool speed-vac until the volume of 10 μl and added μl 5% FA
when ready for MS analysis.
2.7.3. Mass spectrometry and software analysis
Trypsin-digested peptides of Jurkat samples were analyzed for 90 min
by HPLC coupled with LC-MS/MS using nano-spray ionization. The nano-
spray ionization experiments were performed using a Triple-Tof 5600
hybrid mass spectrometer (AB SCIEX, Framingham, MA-USA) interfaced
with an Agilent 1200 capillary nano-scale reversed-phase HPLC system
(Agilent Technologies, Santa Clara, CA-USA). All collected data were
analyzed using MASCOT (Matrix Sciences), Peak View and Protein Pilot
4.0 (AB SCIEX, Framingham, MA-USA) for peptide identifications.
2.8. Microscopy
Jurkat T cells incubated with diamide and/or Syk inhibitors were
pelleted and washed twice in PBS. Then they were fixed for 60 min in
4% PFA. Cells were washed two times and permeabilized in PBS
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10 min. After the incubation, all non-specific bindings were blocked
by an incubation for 60 min at 37 °C with 5% goat serum/PBS.
Permeabilized Jurkat T cells were stained by using 1:100 anti-
phosphotyrosine antibodies (Santa Cruz Biotechnology, Santa Cruz,
CA-USA) and 1:250 mouse FITC-conjugated secondary antibody
(Sigma-Aldrich, St. Louis, MO-USA) in PBS/1% goat serum. 1 μg/ml
DAPI (Sigma-Aldrich, St. Louis, MO-USA) was added for 1 min. After la-
beling, resuspended samples were allowed to attach to cover slips coat-
ed with polylysine. The samples were observed with a Olympus BX 51
microscope, UplanFL 60X/1.25 Oil Iris Lens, 479–490 excitation filter
and 505 dichroic filter, 510–550 emission filter. The images were ac-
quired in the NL with an Optronics-Magnafire camera. The merge and
quantification of fluorescence levels were performed using Image J soft-
ware (ver 1.44p).2.9. Cytokine release quantification
After the treatment with 0.3 mM diamide and Syk inhibitors super-
natant of Jurkat T cell and primary T cells (1.5 × 106 cells for each con-
dition) were collected. The concentrations of soluble cytokines (IL-2,
IFNγ, TNFα) in culture supernatants were measured with CBA Flex SetFig. 3. Role of Syk and activity of Syk inhibitors in the Jurkat T cells under oxidative condition. (
munoblot of Jurkat cell Syk phosphorylation time course in oxidative condition; (C): Immunoblo
5 μM (Syk i), at different incubation times (0–180 min). (D): Quantification of tyrosine phosph
phosphotyrosine western blots and expressed as fluorescence arbitrary units. Values are plott
***(p b 0.001) indicate the incubation time that determines a statistically significant change by(BD Biosciences, Mountain View, CA, USA). It was used as powerful
and accurate analysis to quantify multiple cytokines from the same
sample simultaneously. The analyses were performed with the FACS
CANTO (BD Biosciences, Mountain View, CA, USA).
2.10. Membrane receptor analysis
T cell functional studies were made by measuring markers
expressed on the cell surface of the treated cells. The different ex-
pression of several surface receptors like CD25 (IL-2 receptor),
CD62L (L-Selectine), HLA-DR, CD45RA+ and CD45RO+ were stud-
ied with specific antibodies for each marker and were purchased
from BD Biosciences (Mountain View, CA, USA). They were analyzed
with flow cytometry FACS CANTO (BD Biosciences, Mountain View,
CA-USA). Experimental data analysis was performed with BD FACS
DIVA™ (BD Biosciences, Mountain View, CA-USA).
2.11. Statistical analysis
Data were analyzed by t-test performed using Microsoft Excel. All
the results were expressed as means +/− SD. p b 0.05 was considered
statistically significant.A): Immunoblot of Jurkat cell Syk expression time course in oxidative condition; (B): im-
t of Jurkat T cells treatedwith 0.3mMdiamide, in the absence or presence of Syk inhibitors
orylation levels was performed by IR fluorescence detection (Odyssey, Licor, USA) of anti-
ed as mean ± standard deviation of 3 separate experiments. *(p b 0.05), **(p b 0.01) and
t-student test in comparison to the control sample.
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3.1. SH group oxidation elicits a tyrosine phosphorylation response in Jurkat
T cell proteins
Diamide is a specific –SH group oxidant that, forming intermediate
thiyl radicals,mainly generates reversible disulfide bonds. Its concentra-
tion was chosen to observe those changes avoiding cell toxicity (see
next paragraph). Jurkat T cells were treated with 0.3 mM diamide. Pro-
tein –SH group oxidation and tyrosine phosphorylation changes at dif-
ferent incubation times (15, 30, 60, 120 and 180 min) were measured
and both peaked after 30′ incubation (Fig. 1). Of note, those changes
are very similar to the response observed in erythrocytes, which display
the lowest GSH levels after 30 min and restore basal GSH levels within
60 min [25]. No apparent changes in protein serine phosphorylation
have been observed under the same conditions (data not shown).
3.2. Proteomic analysis of tyrosine phosphorylation response in Jurkat T cell
proteins
To identify the protein tyrosine phosphorylation sites involved the
oxidative and phosphorylation changes initiated by diamide we used
different proteomic approaches.
We initially used MALDI-ToF to identify the protein bands showing
oxidative and/or phosphorylation changes (Fig. 1). This analysis showed
a great complexity of the cellular response activated by oxidation: ki-
nases, structural proteins, and heat shock proteins (HSPs) seemed to
be the most intensely affected (Fig. 9 in supplementary data and
Table 1), but the analytical limits of this proteomic approach (low spec-
ificity due to the difficulty in co-identifying protein bands stained by
western blot and Coomassie) persuaded us to carry out a more specific
investigation.
In order to gain additional information we designed experiments
based on MS/MS identification of immunoprecipitated Tyr phos-
phopeptides. Phosphorylation analysis was performed in order to de-
tect the unique phosphoTyr-sites of proteins. This phosphorylation-Fig. 4. Interference and phase contrastmicroscopy of Jurkat T cells exposed to diamide and Syk in
(C): Jurkat T cells treated with 0.3 mM diamide. (Panel D): Jurkat T cells treated with 0.3 mM d
FITC-conjugated anti-phosphotyrosine and DAPI.targeted tandem mass spectrometry strategy was focused on scanning
the ionized peptides through different quadrupoles: the ions are
fragmented through low-energy collisions and then scanned with a
fixed offset to the modification and the charge state of the precursor
peptide. It permitted to identify 36 proteins and 46 phosphopeptides
in untreated and treated samples. Table 2 shows the distinctive Tyr
phosphopeptides identified by MS/MS of proteins that we found in
treated samples. Our analysis provided preliminary evidences on sever-
al plausible effectors such as Lck, AP endonucleases, and Cdk3. Despite
these promising results, proteomic data did not provide sufficient infor-
mation to support a prediction of the cellular effects of protein phos-
phorylation changes induced by a transient –SH group oxidation. We
therefore decided to perform further analysis to obtain a better func-
tional description of the cellular responses (see following sections).
3.3. Cell viability and MTT reduction following diamide treatment
In order to confirm the viability of Jurkat T cells after diamide treat-
ment, Trypan blue exclusion test was performed (Fig. 2A) showing that
viabilitywas not apparently affected. Fig. 2B shows the capability of cells
to reduce Thiazolyl Blue Tetrazolium Bromide (MTT) at different incu-
bation times with diamide. This test is in agreement with the temporal
changes of protein –SH groups, showing a transient decrease of the cel-
lular reductive activity after 30 min and a subsequent recovery within
60 min.
At higher concentration of diamide increasing loss of viability was
observed. Moreover apoptosis index was analyzed by Annexin V assay
showing that diamide treatment did not induce apoptotic phenomena
(data not shown).
3.4. Spleen tyrosine kinase (Syk) is involved in tyrosine phosphorylation
changes induced by –SH group oxidation
Next we investigated the role of Syk in the tyrosine phosphorylation
cascade triggered by diamide. Fig. 3A shows that Syk appears to behibitors. (A): Jurkat T cells (Control). (B): Jurkat T cells incubatedwith 5 μMSyk inhibitors.
iamide and pre-incubated with 5 μM Syk inhibitors. All the conditions were stained with
Fig. 5. Quantification analysis of TNFα, IFNγ and IL-2 cytokines released by Jurkat T cells.
Jurkat T cells were treated with 0.3 mM diamide in the presence or absence of 5 μMM
Syk inhibitors (Syk i). Each condition supernatant was collected, in order to evaluate the
release of cytokines at different incubation times. Values are the means of 3 experiments.
All data are expressed by ratio W/V in picograms (pg/ml). Medians and P values which
were found to be statistically significant by the t-student test are shown (*p b 0.05,
**p b 0.01, ***p b 0.001). (A): Jurkat T cell supernatants were probed against TNFα by
CBA Flex Set method (BD Falcon). (B): Jurkat T cell supernatants were probed against
IFNγ by the CBA Flex Set method (BD Falcon). (C) Jurkat T cell supernatants were probed
against IL-2 by the CBA Flex Set method (BD Falcon).
783C. Secchi et al. / Cellular Signalling 27 (2015) 777–788constitutively expressed in Jurkat T cells and that its expression is not
apparently affected by diamide treatment.
On the other hand, Syk appears to be strongly phosphorylated in the
presence of diamide (Fig. 3B). Syk inhibition determines a profound ef-
fect on the Tyr phosphorylation response (Fig. 3C, D). Additionally, ex-
periments were performed with inhibitors of Lyn, which should be
located upstream of Syk, and showed a strong decrease of Tyr phos-
phorylation (data not shown). Fluorescence microscopy of Jurkat T
cells stained with anti-phosphotyrosine antibodies was also used to
show the Tyr phosphorylation response induced by –SH group oxida-
tion. Fig. 4 shows a homogeneous response of Jurkat T cells to diamide
confirming the transient behavior observed with western blot analysis
(Fig. 1A) and the marked effect of Syk inhibition (Fig. 4C, D and Fig. 10
in the Supplementary data).
3.5. Effects of –SH group oxidation and Syk inhibition on cytokine release
and receptor expression
Weperformed a functional characterization of Jurkat T cells measur-
ing by FACS analysis a set of released cytokines and the surface expres-
sion of different receptors.
Diamide exposure or Syk inhibition did not induce measurable
changes in TNF release. Syk inhibitors induced a detectable decrease of
TNF release only in basal samples (Fig. 5A). On the contrary, diamide
stimulated the release of both interferon γ (IFNγ) and interleukin 2
(IL2) while Syk inhibition reduced the effects of diamide, in particular
after 60 min incubation (Fig. 5B and C).
Different cell surface receptors showed variable responses to oxida-
tion: the surface expression of CD62L, HLA-DR, CD45RA+was reduced
following diamide treatment (Figs. 6 and 7). Syk inhibition caused a fur-
ther decrease of this effect on CD62L andHLA-DR receptor (Figs. 6B1 and
7A1) expression, while it had not a measurable effect on CD45RA+
(Fig. 7B1). On the contrary, diamide treatment caused an increase of ex-
pression of CD25 receptor (Fig. 6A1) and Syk inhibition reverted this
phenomenon. The responses displayed different temporal patterns
and were differently significant (Figs. 6A1, B1, 7A1, B1). In some in-
stances, such as CD62L and HLA-DR, Syk inhibition caused a significant
variation of the basal levels of surface receptors.
4. Discussion
T lymphocytes appear to respond to redox stress in inflammation
and other pathological conditions [31]. Besides the involvement of
redox-sensitive NF-kB and Nrf2 transcription factors in T cell activation
[68,69] and additional evidence indicating the involvement of ROS in T
cell activation andproliferation [70–72], very limited information is cur-
rently available on the regulatory and signalingmechanisms involved in
ROS response. To generate specific responses, ROS need to interact with
molecular sensors, likely to be cysteine residues located in regulatory el-
ements. Through the formation of a reversible disulfide bond, sensors
activates intracellular signaling pathways upon detection of redox
changes [2,6,8]. To explore this mechanism, Jurkat T cells were treated
with non-cytotoxic concentrations of diamide, a specific oxidant of
thiol groups inducing the formation of reversible disulfide bonds. Pro-
tein Tyr phosphorylation changes were then monitored in parallel to
the oxidation of protein sulfhydryl groups.
Protein Tyr phosphatase (PTPs) inhibition and Tyr kinase activation
are the two mechanisms expected to regulate protein phosphorylation
changes. The regulatory cysteine residues of some PTPs display a rela-
tively low reactivity (1000-fold lower than GSH) to oxidants [52]. Keep-
ing in consideration the high intracellular concentration of GHS, PTPs
should therefore be inactivated only at very high concentrations of
ROS [8].
Both Lyn and Syk tyrosine kinases appear to respond to redox chang-
es: Lyn has been demonstrated to be a redox sensor in neutrophils [51]
and Syk has been demonstrated to be reversibly activated by –SHreagents in erythrocytes [26] and B cells [73]. In the present report we
have observed that, following a low-dose diamide treatment, a transient
sulfhydryl group oxidation was paralleled by intense protein Tyr phos-
phorylation changes. Both protein Tyr phosphorylation and sulfhydryl
group oxidation showed a reversible response peaking at 30 min. Inter-
estingly, Lyn and Syk kinase inhibitors efficiently reverted those chang-
es. The effect of both inhibitors can be explained considering that Syk
can be up-regulated by Lyn in different cell models [74,75]. The finding
that Sykwas Tyr-phosphorylated following diamide treatment substan-
tiated its involvement in oxidant response [26].
These results may be of particular interest for the understanding of
Syk inhibitors mechanism of action in the treatment of rheumatoid ar-
thritis, which has been often associated with ROS generation [76,77].
To gain insight into the cellular mechanisms involved in the redox re-
sponse of T cells, we conducted a comprehensive investigation of the
Tyr phosphorylation changes using proteomic approaches. This study
provided preliminary information on several potential players such as
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allow a prediction on the functional effects of protein phosphorylation
changes that follow a transient sulfhydryl group oxidation.Fig. 6. CD25 and CD62L surface receptor expression of Jurkat T cells exposed to diamide and Sy
5 μM Syk inhibitors (Syk i) at different incubation times. Values are plotted as mean ± standar
ulation (%). Medians and P valueswhichwere found to be statistically significant by the t-stude
were stained against surface-CD25 and surface-CD62L analyzed by FACS. (7A2, 7B2): Represent
anti-human CD25 and CD62L. (7A3, 7B3): Representative flow cytometric density plot of Jurkat T
and CD62L. (7A4, 7B4): Representative flow cytometric density plot of Jurkat T cells treatedwith
and CD62L.To obtain functional data, we also monitored the variations of cyto-
kine release and expression of a set of surface receptors following di-
amide treatment. In Jurkat T cells, TNF release was not affected byk inhibitors. Jurkat T cells were treated with 0.3 mM diamide in the presence or absence of
d deviation of 3 separate experiments. All data are expressed as percent of total cell pop-
nt test are shown (* p b 0.05, ** p b 0.01, *** p b 0.001). (7A1 and 7B1): Jurkat T cell samples
ative flow cytometric density plot of untreated Jurkat T cells stained with FITC-conjugated
cells treatedwith 0.3mMdiamide for 1 h stainedwith FITC-conjugated anti-human CD25
0.3mMdiamide and Syk inhibitor for 1 h stainedwith FITC-conjugated anti-human CD25
Fig. 7.HLA-DR and CD45RA+ surface receptor expression of Jurkat T cells exposed to diamide and Syk inhibitors. Jurkat T cells were treated with 0.3 mM diamide in the presence or ab-
sence of 5 μMSyk inhibitors (Syk i.) at different incubation times. Values are plotted asmean± standard deviation of 3 separate experiments. All data are expressed as percent of total cell
population (%). Medians and P values which were found to be statistically significant by the t-student test are shown (*p b 0.05, **p b 0.01, ***p b 0.001). (8A1, 8B1): Jurkat T cell samples
were stained against surface-HLA-DR and surface-CD45RA+ analyzed by FACS. (8A2, 8B2): Representative flow cytometric density plot of untreated Jurkat T cells stained with FITC-con-
jugated anti-human HLA-DR and CD45RA+. (8A3, 8B3): Representative flow cytometric density plot of Jurkat T cells treated with 0.3 mM diamide for 1 h stained with FITC -conjugated
anti-human HLA-DR and CD45RA. (8A4, 8B4): Representative flow cytometric density plot of Jurkat T cells treated with 0.3 mM diamide and Syk inhibitor for 1 h stained with FITC
-conjugated anti-human HLA-DR and CD45RA.
785C. Secchi et al. / Cellular Signalling 27 (2015) 777–788diamide while IFNγ and IL2 peaked in correspondence of the maximal
sulfhydryl oxidation and Tyr phosphorylation responses. Expression of
CD25 (α-chain of the IL2 receptor), a late activation receptor, showedthe same behavior. On the contrary, HLA-DR, an element of the MHC
II, was transiently down-regulated by diamide. Diamide also caused a
negative and transient effect on the surface expression of CD62L, a
Fig. 8. Thiol group-based redox regulationmodel of phosphotyrosine changes in T cells. ROS from different sources, such asmacrophages, maymodulate tyrosine cascade in Jurkat T cells.
Oxidation of cysteinil –SH groups could generate a direct activation of Syk or an inhibition of tyrosine phosphatases as CD45. CD45 block promotes phosphorylation of Lyn that activates
Syk. Syk has a key role in the subsequent phosphotyrosine events. Thesemolecular phenomenamay involve a variegate number of effectors and generate a cellular response that increases
the production of IL2 and the expression of its receptor (CD25) or decreases other receptors (CD62L, HLA, CD45).
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phosphatase CD45RA+ also displayed a down-expression following di-
amide treatment. It is interesting to note that CD45 specifically dephos-
phorylates Lyn, consequently down-regulating its activity [78]. A down-
regulation of CD45 should then induce an up-regulation of Lyn and con-
sequently of Syk [74,79]. This finding is in agreement with the powerful
effect of Lyn and Syk inhibitors on the phosphorylation response that
follows diamide treatment. The efficiency of Syk inhibitors in suppress-
ing most of the observed cellular responses to redox stress is also in
agreement with a sequential involvement of Lyn and Syk.
In conclusion, in Jurkat T cells a transient oxidation of protein sulfhy-
dryl groups induces a complex protein Tyr phosphorylation response,
accompanied by intense and reversible changes of cytokines release
and receptors exposure. Although the physiological meaning of the ob-
served changes is still difficult to assess, in Fig. 8wepropose an interpre-
tation of the T cell response to the redox stress generated during
inflammation: i) the observed release of IFNγ by T cells may activate
macrophages eliciting a positive feedback for ROS production; ii) the re-
lease of IL2 and the over-expression of IL2 receptor may induce T cell
proliferation but also further macrophage and killer cells activation;
iii) the down-regulation of CD62L receptor and the lack of effects on
TNF release indicate a multifaceted response of T cells; iv) the putative
effect of CD45 inhibition on Lyn and Syk activation have also been
depicted.
The interpretation of our results should also take into account the re-
sponse of different T cells subsets and the modulation exerted by the
large number of regulatory signals that may accompany the production
of ROS during inflammation.
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